Easier Access to Autoimmune and Blood Disorder Drugs in Medicare
This act aims to improve access to medications for autoimmune diseases, hemophilia, and Von Willebrand disease for individuals covered by Medicare. Starting in 2027, prescription drug plans will be required to cover these drugs, and the need for re-authorization will be limited to once every 12 months, reducing bureaucracy and speeding up treatment.
Key points
All Medicare Part D prescription drug plans will be required to cover drugs for autoimmune diseases, hemophilia, and Von Willebrand disease starting in 2027.
The requirement for prior authorization for these specific drugs will be limited to once every 12 months, easing continuous treatment and reducing administrative burden for patients and doctors.
Exemptions apply for drugs typically used for 12 months or less, opioids, benzodiazepines, barbiturates, carisoprodol, and drugs requiring risk evaluation and mitigation strategies.
Introduced
Citizen Poll